Circulating Nucleic Acids as Liquid Biopsies and Noninvasive Disease Biomarkers¶
Chapter 503 | Part 20: Emerging Topics in Clinical Medicine
KEY CLINICAL POINTS¶
- Cell-free DNA (cfDNA) and circulating tumor DNA (ctDNA) are pivotal in oncology for noninvasive tumor genotyping, minimal residual disease (MRD) detection, and treatment monitoring.
- Donor-derived cfDNA (dd-cfDNA) is a critical biomarker for acute allograft rejection in transplantation, with thresholds (e.g., ≥ 0.25%) guiding noninvasive surveillance.
- Noninvasive prenatal testing (NIPT) using cfDNA enables detection of fetal aneuploidy, microdeletions, and single-gene disorders with high sensitivity and specificity.
- Next-generation sequencing (NGS) and digital droplet PCR (ddPCR) are key technologies for cfDNA analysis, offering high analytical sensitivity and rapid turnaround.
- Microbial cfDNA analysis in transplant recipients can monitor immune status and detect opportunistic infections, with Anelloviridae load correlating with immunosuppression levels.
1. DEFINITION & OVERVIEW¶
Liquid biopsies refer to the analysis of circulating nucleic acids (e.g., cfDNA, ctDNA, cfRNA) in bodily fluids for noninvasive disease detection, monitoring, and treatment response assessment. These methods are increasingly used in oncology, transplantation, and obstetrics to replace or complement invasive procedures.
Viral Genomic Abundance by Drug Dose¶
| Drug Dose (Valganciclovir) | Viral Family | Percentage |
|---|---|---|
| 0–300 mg | Herpesvirales | 34% |
| 0–300 mg | Caudovirales | 15% |
| 300–600 mg | Anelloviridae | 30% |
| 600–900 mg | Adenoviridae | 10% |
| >900 mg | Polyomaviridae | 2% |
Rejection Event Detection by dd-cfDNA Thresholds¶
| Rejection Type | dd-cfDNA Threshold (%) | AUC |
|---|---|---|
| Mild Rejection | 0.25% | 0.60 |
| Moderate-to-Severe Rejection | 0.25% | 0.83 |
| Rejection Type | dd-cfDNA Threshold (%) | AUC |
|---|---|---|
| Severe Rejection | 0.25% | 0.95 |
1.1 Clinical Applications¶
Liquid biopsies are applied in oncology for early cancer detection, tumor genotyping, MRD monitoring, and treatment response assessment. In transplantation, they detect acute rejection via dd-cfDNA levels and monitor microbial diversity. In obstetrics, they screen for fetal aneuploidy, microdeletions, and single-gene disorders.
1.2 Technical Basis¶
Circulating nucleic acids originate from apoptotic/necrotic cells, tumors, or microbial sources. cfDNA is fragmented and released into plasma, while ctDNA is a subset of cfDNA derived from tumors. cfRNA provides insights into gene expression during pregnancy and disease.
2. EPIDEMIOLOGY¶
cfDNA and ctDNA are universally present in bodily fluids, with concentrations varying by tissue type and disease state. dd-cfDNA levels correlate with immunosuppression intensity in transplant recipients. NIPT is widely adopted globally, with over 100,000 tests performed annually in the U.S. alone.
2.1 Cancer Burden¶
Early detection of cancers like lung, colorectal, and breast improves outcomes. ctDNA detection rates vary by tumor type, with NSCLC and ovarian cancer showing high sensitivity for MRD monitoring.
2.2 Transplantation¶
Acute rejection occurs in ~10–20% of solid organ transplant recipients. dd-cfDNA levels rise 2–4 days post-transplant, peaking at 1–2 weeks, then stabilizing unless injury occurs.
3. ETIOLOGY & PATHOPHYSIOLOGY¶
cfDNA is released from apoptotic/necrotic cells, tumors, or microbial sources. Tumor-derived ctDNA reflects clonal evolution and mutational heterogeneity. dd-cfDNA arises from donor tissues and indicates graft injury. Microbial cfDNA reflects immune status and infection risk.
3.1 Tumor Biology¶
Tumors release ctDNA into circulation, which carries somatic mutations, structural variants, and epigenetic markers. ctDNA levels correlate with tumor burden and response to therapy.
3.2 Immunosuppression¶
Immunosuppressive drugs alter virome composition, with Anelloviridae load inversely correlating with immunosuppression intensity. dd-cfDNA levels reflect graft injury and rejection risk.
4. CLINICAL FEATURES¶
In oncology, ctDNA levels correlate with tumor burden and treatment response. In transplantation, dd-cfDNA elevation indicates acute rejection or graft injury. In obstetrics, cfDNA abnormalities signal fetal aneuploidy or chromosomal abnormalities.
4.1 Oncology¶
ctDNA levels increase with tumor progression and decrease after effective therapy. Elevated ctDNA is associated with poor prognosis and resistance to targeted therapies.
4.2 Transplantation¶
dd-cfDNA levels rise with acute rejection, with thresholds (e.g., ≥ 0.25%) predicting rejection risk. Microbial cfDNA spikes indicate infection or immune dysregulation.
4.3 Obstetrics¶
cfDNA abnormalities in maternal serum detect fetal aneuploidy (e.g., trisomy 21) and microdeletions. cfRNA analysis predicts preeclampsia and preterm birth.
5. DIFFERENTIAL DIAGNOSIS¶
In oncology, ctDNA must be distinguished from clonal hematopoiesis (CH) background mutations. In transplantation, dd-cfDNA elevation may reflect infection, graft injury, or technical artifacts. In obstetrics, cfDNA anomalies must be differentiated from maternal mosaicism or false positives.
5.1 Oncology¶
CH mutations (e.g., DNMT3A, TET2) can mimic tumor-derived ctDNA. Sequencing of tumor tissue and plasma cfDNA helps distinguish true MRD from background noise.
5.2 Transplantation¶
dd-cfDNA elevation may arise from infection, graft injury, or technical errors. Confirmatory biopsies or microbial cfDNA analysis are required for accurate diagnosis.
6. INVESTIGATIONS & DIAGNOSIS¶
Diagnostic methods include next-generation sequencing (NGS), digital droplet PCR (ddPCR), and targeted assays (e.g., Guardant360, FoundationOne Liquid CDx). cfDNA analysis is validated for ctDNA detection, dd-cfDNA monitoring, and fetal aneuploidy screening.
NIPT Detection Rates for Fetal Aneuploidy¶
| Aneuploidy Type | Sensitivity (%) | PPV (%) |
|---|---|---|
| Trisomy 21 | 99.9 | 99.9 |
| Trisomy 18 | 98.5 | 98.5 |
| Trisomy 13 | 97.0 | 97.0 |
6.1 Techniques¶
NGS enables whole-genome or targeted sequencing of cfDNA, while ddPCR quantifies specific mutations. cfRNA analysis uses RNA-seq or qPCR to assess gene expression.
6.2 Assays¶
Approved assays include Guardant360 (NSCLC), FoundationOne Liquid CDx (ovarian cancer), and Signatera MRD (colorectal cancer). NIPT platforms like Natera’s Panorama detect fetal aneuploidy with >99% sensitivity.
7. MANAGEMENT & TREATMENT¶
ctDNA monitoring guides personalized oncology therapies, while dd-cfDNA levels inform immunosuppressive adjustments. NIPT results drive prenatal management decisions, including invasive testing or termination.
7.1 Oncology¶
ctDNA levels are used to monitor response to targeted therapies (e.g., EGFR inhibitors) and detect MRD. Early molecular response (e.g., 2-log ctDNA reduction) predicts survival outcomes.
7.2 Transplantation¶
dd-cfDNA thresholds (e.g., ≥ 0.25%) guide noninvasive rejection surveillance. Adjustments to immunosuppressive regimens are made based on dd-cfDNA trends.
7.3 Obstetrics¶
NIPT results inform prenatal management, including confirmatory testing (amniocentesis) or termination. cfRNA analysis may guide interventions for preeclampsia or preterm birth.
8. PROGNOSIS & COMPLICATIONS¶
Early ctDNA detection improves cancer outcomes, while elevated dd-cfDNA predicts rejection risk. False positives in NIPT may lead to unnecessary invasive testing. Microbial cfDNA misinterpretation could delay infection treatment.
8.1 Oncology¶
ctDNA levels correlate with disease progression and survival. MRD detection identifies high-risk patients for adjuvant therapy, improving outcomes.
8.2 Transplantation¶
Persistent dd-cfDNA elevation after rejection treatment indicates treatment failure. Early detection of graft injury enables timely intervention.
8.3 Obstetrics¶
False-positive NIPT results may lead to anxiety and invasive testing. cfRNA misinterpretation could delay management of obstetric complications.
9. SPECIAL CONSIDERATIONS¶
In pregnancy, cfDNA testing is safe and noninvasive. In elderly patients, ctDNA analysis may be less sensitive due to clonal hematopoiesis. In transplant recipients, dd-cfDNA monitoring must account for immunosuppressive drug effects.
9.1 Pregnancy¶
NIPT is preferred over invasive testing for fetal aneuploidy. cfDNA levels in maternal serum are influenced by gestational age and fetal fraction.
9.2 Transplant Recipients¶
dd-cfDNA levels are influenced by immunosuppressive drugs (e.g., tacrolimus, valganciclovir). Anelloviridae load inversely correlates with immunosuppression intensity.
10. KEY POINTS & CLINICAL PEARLS¶
- ctDNA and dd-cfDNA are noninvasive biomarkers for cancer, transplantation, and prenatal diagnosis. 2. dd-cfDNA thresholds (e.g., ≥ 0.25%) guide rejection surveillance. 3. NIPT using cfDNA detects fetal aneuploidy with high sensitivity. 4. Microbial cfDNA analysis aids in transplant infection monitoring. 5. Technical validation (e.g., NGS, ddPCR) is critical to minimize false positives.